ReviewThe AAPS journal2006
Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.
Review in The AAPS journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines.Asian journal of pharmaceutical sciences · 2026Review
- Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.Pharmaceutical research · 2018Article
- Innovations in gene and growth factor delivery systems for diabetic wound healing.Journal of tissue engineering and regenerative medicine · 2018Review
- Current Progress of Virus-mimicking Nanocarriers for Drug Delivery.Nanotheranostics · 2017Review
- Restriction-based Multiple-fragment Assembly Strategy to Avoid Random Mutation during Long cDNA Cloning.Journal of Cancer · 2015Article
- Vascular gene transfer from metallic stent surfaces using adenoviral vectors tethered through hydrolysable cross-linkers.Journal of visualized experiments : JoVE · 2014Article
- Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery.Molecular therapy. Nucleic acids · 2014Article
- Integration of biosensors and drug delivery technologies for early detection and chronic management of illness.Sensors (Basel, Switzerland) · 2013Review
- Assessment of hazard risk associated with the intravenous use of viral vectors in rodents.Comparative medicine · 2012Article
- Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.Biomaterials · 2012Review
- Viral and nonviral delivery systems for gene delivery.Advanced biomedical research · 2012Article
- Suppression of tumor growth in xenograft model mice by programmed cell death 4 gene delivery using folate-PEG-baculovirus.Cancer gene therapy · 2010Article
- Building Cell Selectivity into CPP-Mediated Strategies.Pharmaceuticals (Basel, Switzerland) · 2010Review
- The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2008Article
- Liposome-mediated cellular delivery of active gp91(phox).PloS one · 2007Article
- Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells.Molecular pharmaceuticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In comparison to classical medicines, gene therapy has the potential to mediate the highest possible level of therapeutic specificity. Every normal or diseased cell can switch on or off a gene expression cassette in a tissue-, disease-, and time-dependent fashion, by use of specific transcription factors that are active only in a given unique situation. In practice, we face the problem in realizing the concept: the delivery of nucleic acids into target cells is very ineffective and presents a formidable challenge. Key issues for future developments include improved targeting, enhanced intracellular uptake, and reduced toxicity of gene vectors. The currently used classes of vectors have complementary characteristics, such as high intracellular efficiency of viral vectors on the one hand and low immunogenicity and greater flexibility of nonviral vectors on the other hand. The merge of viral and nonviral vector technologies is highlighted as an encouraging strategy for the future; concepts include chemically modified viral vectors ("chemo-viruses") and synthesis of virus-like systems ("synthetic viruses"). Examples for the development of vectors toward artificial synthetic viruses are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.